<DOC>
	<DOCNO>NCT00775684</DOCNO>
	<brief_summary>This study evaluate exenatide , sitagliptin , glimepiride treatment high blood sugar patient impair fast glucose early type 2 diabetes . The purpose study determine exenatide sitagliptin increase amount insulin make pancreas compare glimepiride . It hypothesize exenatide sitagliptin sustain increase amount insulin make pancreas comparison glimepiride .</brief_summary>
	<brief_title>Effect Exenatide , Sitagliptin Glimepiride Functional ß -Cell Mass</brief_title>
	<detailed_description>The incidence type 2 diabetes ( T2D ) reach epidemic proportion throughout world . In United States 1.5 million new case diabetes diagnosed 2005 , estimate prevalence disease 20 million . Another 54 million Americans believe impaired fasting glucose , represent `` pre-diabetic '' state increase risk progression overt diabetes . T2D ultimately result inadequate mass functional beta-cells , insufficient beta-cell compensation insulin resistance lead development impair glucose tolerance eventually diabetes . Autopsy study demonstrate decreased beta-cell mass occur fast glucose &gt; 110 mg/dl , consistent functional study demonstrate decrease beta-cell ( insulin ) secretory capacity begin range impair fast glucose . Strategies might preserve expand functional beta-cell mass vivo would expect reverse progressive deterioration blood glucose control see diabetes . One strategy involve incretin hormone glucagon-like peptide-1 ( GLP-1 ) , trophic islet beta-cells , pro-proliferative anti-apoptotic effect . However , know whether increase GLP-1 effect preserve enhance functional beta-cell mass human . This proposal determine effect increase GLP-1 level functional beta-cell mass human subject impair fast glucose ( fast glucose 110 - 126 mg/dl ) early T2D ( fast glucose 127 - 149 mg/dl ) critical window exists reverse beta-cell deterioration . GLP-1 effect promote administration either GLP-1 analog , exenatide , increase endogenous GLP-1 level administration oral DPP4 inhibitor sitagliptin 6-month period . To control effect exenatide sitagliptin normalization blood glucose , subject randomize receive exenatide , sitagliptin sulfonylurea glimepiride , latter first-line anti-diabetogenic agent serve active comparator .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Male female patient age 18 70 year . 2 . Ability provide write informed consent 3 . Mentally stable able comply procedure study protocol 4 . Clinical history compatible impaired fasting glucose early T2D define plasma glucose concentration 110159 mg/dl follow 12 hour overnight fast perform antidiabetogenic agent least 2 week ( 6 week thiazolidinediones ) 5 . Stable body weight ( + 5 % ) least 2 week 6 . Female Patients : Agree use adequate contraception reproductively capable . Adequate contraception include either hormonal barrier method , surgical sterilization . 1 . Diagnosis type 1 diabetes 2 . Receiving insulin , exenatide ( Byetta® ) , sitagliptin ( Januvia® ) treatment take &gt; 2 oral antidiabetogenic agent treatment diabetes 3 . BMI &gt; 44 kg/m2 4 . Allergy sulfacontaining compound 5 . Uncontrolled hypertension ( SBP &gt; 160 DBP &gt; 100 mmHg ) 6 . Uncontrolled hyperlipidemia ( triglyceride &gt; 500 LDL &gt; 160 mg/dl ) 7 . Elevation liver function test &gt; 2 time upper limit normal 8 . Estimated GFR &lt; 55 ml/min/1.73m2 ( 46 ) 9 . Hyperkalemia ( serum potassium &gt; 5.5 mmol/L ) 10 . Moderate anemia ( hemoglobin concentration &lt; 12 g/dl men &lt; 11 g/dl woman ) 11 . Female patient : pregnant lactate 12 . Hepatic cirrhosis 13 . Known active alcohol substance abuse 14 . Active cardiovascular disease 15 . Use investigational agent within 6 week baseline visit 16 . Any medical condition , opinion investigator , interfere safe completion trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Exenatide</keyword>
	<keyword>Sitagliptin</keyword>
	<keyword>Glimepiride</keyword>
	<keyword>Glucagon-Like Peptide-1</keyword>
	<keyword>Impaired Fasting Glucose</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Beta-cell Function</keyword>
	<keyword>Beta-cell Secretory Capacity</keyword>
	<keyword>Glucose-potentiated arginine</keyword>
</DOC>